Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Alzheimer's & Dementia

• Publication date

  2015-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.jalz.2014.07.156PMID 25301682PMCID PMC4387108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Active immunotherapy options for Alzheimer’s disease

  2014cited by this paper
• Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Stability of amyloid‐β peptides in plasma and serum

  2012cited by this paper
• Improved protocol for measurement of plasma β‐amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients

  2012cited by this paper
• Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease

  2012cited by this paper
• Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

  2011influential reference
• Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline.

  2011influential reference
• A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

  2011cited by this paper
• Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

  2010cited by this paper
• Random Effects Models for Longitudinal Data

  2010cited by this paper
• Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers

  2010cited by this paper
• Performance Characteristics of Plasma Amyloid-β 40 and 42 Assays

  2009cited by this paper
• Ten-year change in plasma amyloid beta levels and late-life cognitive decline.

  2009cited by this paper
• Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study

  2008cited by this paper
• Plasma amyloid β protein is elevated in late-onset Alzheimer disease families

  2008cited by this paper
• Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families.

  2008cited by this paper
• Effects of Simvastatin on Cerebrospinal Fluid Biomarkers and Cognition in Middle-Aged Adults at Risk for Alzheimer's Disease

  2008cited by this paper
• Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease

  2008cited by this paper
• Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.

  2008cited by this paper
• The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.

  2007cited by this paper
• Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease

  2007cited by this paper
• Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

  2007cited by this paper
• Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid

  2006cited by this paper
• Vitamin E and donepezil for the treatment of mild cognitive impairment.

  2005cited by this paper
• [P‐019]: Plasma amyloid beta protein 42 in non‐demented persons aged 75‐years: Effects of concomitant medication and medial temporal lobe atrophy

  2005cited by this paper
• Plasma Levels of β-Amyloid(1-40), β-Amyloid(1-42), and Total β-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins

  2004cited by this paper
• Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

  2004cited by this paper
• Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.

  2004cited by this paper
• Multivariate longitudinal models for complex change processes

  2004cited by this paper
• Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans

  2003cited by this paper
• Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.

  2003cited by this paper
• Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein.

  2003cited by this paper
• Treatment with Simvastatin in Patients with Alzheimer’s Disease Lowers Both α- and β-Cleaved Amyloid Precursor Protein

  2003cited by this paper
• Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

  2003cited by this paper
• Plasma amyloid β protein 1–42 levels are increased in old Down Syndrome but not in young Down Syndrome

  2003cited by this paper
• Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans.

  2003cited by this paper
• Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels

  2003cited by this paper
• Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk

  2003cited by this paper
• Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome

  2001cited by this paper
• Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.

  2001cited by this paper
• Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease

  2001cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo

  2001cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

  2001cited by this paper
• Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

  2000cited by this paper
• Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

  2000cited by this paper
• Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease

  2000cited by this paper
• Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome

  1999cited by this paper
• Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease.

  1999cited by this paper
• Increased plasma amyloid β protein 1–42 levels in Down syndrome

  1998cited by this paper
• Increased plasma amyloid beta protein 1-42 levels in Down syndrome.

  1998cited by this paper
• Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome

  1997cited by this paper
• Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome.

  1997cited by this paper
• Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

  1996cited by this paper
• Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

  1996cited by this paper
• Random-effects models for longitudinal data.

  1982cited by this paper
• Information Theory and an Extension of the Maximum Likelihood Principle

  1973cited by this paper
• Statistical Methods

  1959cited by this paper

• Hypertension moderates the relationship between plasma beta-amyloid and cognitive impairment: a cross-sectional study in Xi’an, China

  2025cites this paper
• Classification of neurodegenerative diseases using brain effective connectivity and machine learning techniques: a systematic review

  2025cites this paper
• Effects of Probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial

  2024cites this paper
• Plasma levels of phosphorylated tau and neurofilament light chain as potential biomarkers for Alzheimer’s disease: A biochemical analysis in Pakistani population

  2023cites this paper
• The genetic and environmental etiology of blood-based biomarkers related to risk of Alzheimer’s Disease in a population-based sample of early old-age men

  2022cites this paper
• Biomarkers of Activity-Dependent Plasticity and Persistent Enhancement of Synaptic Transmission in Alzheimer Disease: A Review of the Current Status

  2022cites this paper
• Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

  2022cites this paper
• An elaborative NMR based plasma metabolomics study revealed metabolic derangements in patients with mild cognitive impairment: a study on north Indian population

  2021cites this paper
• Can blood amyloid levels be used as a biomarker for Alzheimer’s disease?

  2021cites this paper
• A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population

  2021cites this paper
• Alterations of aqueous humor Aβ levels in Aβ-infused and transgenic mouse models of Alzheimer disease

  2020cites this paper
• Plasma tau protein and Aβ42 level as markers of cognitive impairment in patients with Parkinson's disease.

  2020cites this paper
• Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease

  2020cites this paper
• Dynamic Blood Concentrations of Aβ1–40 and Aβ1–42 in Alzheimer’s Disease

  2020influential citation
• Statins in Neuro-ophthalmology

  2020cites this paper
• Amyloid-β as a Blood Biomarker for Alzheimer’s Disease: A Review of Recent Literature

  2019cites this paper
• The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey

  2019cites this paper
• Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study

  2019influential citation
• Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease.

  2019cites this paper
• Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer’s Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial

  2018cites this paper
• The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease

  2017influential citation
• Peripheral Fluid-Based Biomarkers of Alzheimer’s Disease

  2017cites this paper
• Longitudinal Cerebrospinal Fluid Biomarkers of Alzheimer Disease: Movement Toward the Diagnosis, Prognosis and Staging of Disease

  2017cites this paper
• The role of hypertension and inflammation on the cognitive symptoms of Alzheimer's disease patients

  2016cites this paper
• Regression of ranked responses when raw responses are censored

  2016cites this paper
• Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.

  2015cites this paper
• The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome

  2015cites this paper
• The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

  2015cites this paper
• A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

  2015influential citation
• Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

  2015cites this paper